Guardant Health (GH) said Wednesday that its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines.
The guidelines recommend Shield as an option for patients who decline or have not completed stool-based or visual examination screening tests for colorectal cancer, the company said.
Shares of the company were up 4% in Wednesday's premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments